Operating Segments

9 Months Ended

Sep. 30, 2024

Operating Segments

Operating Segments

Note 7. Operating Segments

The Company maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended
	September 30,
	2024		2023
Revenues
Specialized BioTherapeutics	$	—	$	—
Public Health Solutions		—		130,440
Total	$	—	$	130,440
Income (loss) from Operations
Specialized BioTherapeutics	$	(834,654)	$	(705,753)
Public Health Solutions		(57,611)		(24,819)
Corporate		(972,971)		(1,048,484)
Total	$	(1,865,236)	$	(1,779,056)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	953	$	954
Public Health Solutions		158		159
Corporate		478		476
Total	$	1,589	$	1,589
Other (Expense) Income, Net
Specialized BioTherapeutics	$	1,409	$	1,683
Corporate		144,446		114,671
Total	$	145,855	$	116,354
Share-Based Compensation
Specialized BioTherapeutics	$	20,598	$	27,427
Public Health Solutions		618		994
Corporate		35,416		36,979
Total	$	56,632	$	65,400

	Nine Months Ended
	September 30,
	2024		2023
Revenues
Specialized BioTherapeutics	$	119,371	$	223,870
Public Health Solutions		—		370,677
Total	$	119,371	$	594,547
Income (loss) from Operations
Specialized BioTherapeutics	$	(1,978,464)	$	(2,227,430)
Public Health Solutions		(165,660)		(26,639)
Corporate		(3,582,878)		(3,306,000)
Total	$	(5,727,002)	$	(5,560,069)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	2,859	$	2,979
Public Health Solutions		476		496
Corporate		1,430		1,489
Total	$	4,765	$	4,964
Other (Expense) Income, Net
Specialized BioTherapeutics	$	(22,397)	$	17,696
Corporate		470,189		60,341
Total	$	447,792	$	78,037
Share-Based Compensation
Specialized BioTherapeutics	$	62,210	$	82,281
Public Health Solutions		1,823		2,982
Corporate		110,235		143,813
Total	$	174,268	$	229,076

	As of		As of
	September 30,		December 31,
	2024		2023
Identifiable Assets
Specialized BioTherapeutics	$	45,674	$	272,099
Public Health Solutions		2,387		3,976
Corporate		10,428,918		9,521,251
Total	$	10,476,979	$	9,797,326